Surrozen: completes second closing, raises approximately $95,100,000

What happened

• The filing says that on Oct 20, 2026 Surrozen, Inc. issued a press release announcing certain financial results related to the second tranche closing (the “Second Closing”) under a Securities Purchase Agreement dated Mar 24, 2025.
• The filing says the Second Closing involved the issuance and sale of 5,741,605 shares of common stock, pre-funded warrants to purchase 2,456,500 shares of common stock, and Series E common warrants to purchase 4,099,052 shares of common stock, for aggregate gross proceeds of approximately $95,100,000, before placement agent fees and other expenses.

Key details

• Purchase price per share of common stock: $11.60; purchase price per pre-funded warrant: $11.5999.
• Each pre-funded warrant has an exercise price of $0.0001 per share, is exercisable immediately and will not expire until exercised in full.
• Each Series E common warrant has an exercise price of $11.54 per whole share, is exercisable immediately and expires five years from issuance; no fractional shares will be issued on exercise.
• The filing says the Second Closing was contingent on public announcement of FDA clearance of the company’s Investigational New Drug Application for SZN-8141 (the Second Closing Milestone), which the company announced on Oct 2, 2026. The company agreed to file a registration statement covering resale of the securities no later than 30 calendar days following the Second Closing and to use reasonable best efforts to have it declared effective no later than 90 calendar days (or 120 calendar days if the SEC conducts a full review).

Why it may matter

• The filing reports Item 2.02 (results of operations and financial condition) by way of a press release and Item 3.02 (unregistered sales of equity securities) describing the securities sold, pricing, exercise terms and registration commitments. This filing does not show why the insider traded or why the company acted.